Craig Bijou
Stock Analyst at B of A Securities
(4.73)
# 133
Out of 4,944 analysts
63
Total ratings
60%
Success rate
56.85%
Average return
Main Sectors:
Stocks Rated by Craig Bijou
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RXST RxSight | Maintains: Underperform | $18 → $9 | $8.31 | +8.30% | 2 | Jul 9, 2025 | |
| PRCT PROCEPT BioRobotics | Maintains: Buy | $104 → $84 | $40.38 | +108.02% | 4 | Apr 25, 2025 | |
| TFX Teleflex | Downgrades: Underperform | $235 → $140 | $122.75 | +14.05% | 5 | Mar 4, 2025 | |
| BLCO Bausch + Lomb | Maintains: Underperform | $18 → $17 | $14.18 | +19.93% | 3 | Feb 20, 2025 | |
| GMED Globus Medical | Upgrades: Neutral | $80 → $97 | $62.79 | +54.48% | 4 | Jan 9, 2025 | |
| IART Integra LifeSciences Holdings | Maintains: Underperform | $26 → $18 | $14.12 | +27.48% | 13 | Oct 7, 2024 | |
| ITGR Integer Holdings | Maintains: Buy | $135 → $145 | $109.58 | +32.32% | 3 | Oct 1, 2024 | |
| MMSI Merit Medical Systems | Maintains: Neutral | $92 → $103 | $86.10 | +19.63% | 3 | Sep 16, 2024 | |
| HAE Haemonetics | Initiates: Neutral | $85 | $53.88 | +57.76% | 1 | Sep 11, 2024 | |
| GEHC GE HealthCare Technologies | Maintains: Neutral | $94 → $86 | $75.33 | +14.16% | 2 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $95 | $74.24 | +27.96% | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $36 | $15.71 | +129.15% | 2 | Jan 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 → $45 | $8.85 | +408.47% | 3 | May 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $120 | $3.19 | +3,661.76% | 2 | Mar 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $30 | $5.18 | +479.15% | 5 | Mar 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $17 → $13 | $12.73 | +2.12% | 2 | Mar 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $48 → $42 | $14.11 | +197.66% | 3 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $207 → $230 | $482.35 | -52.32% | 1 | Jan 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $190 → $230 | $378.95 | -39.31% | 4 | Jul 26, 2019 |
RxSight
Jul 9, 2025
Maintains: Underperform
Price Target: $18 → $9
Current: $8.31
Upside: +8.30%
PROCEPT BioRobotics
Apr 25, 2025
Maintains: Buy
Price Target: $104 → $84
Current: $40.38
Upside: +108.02%
Teleflex
Mar 4, 2025
Downgrades: Underperform
Price Target: $235 → $140
Current: $122.75
Upside: +14.05%
Bausch + Lomb
Feb 20, 2025
Maintains: Underperform
Price Target: $18 → $17
Current: $14.18
Upside: +19.93%
Globus Medical
Jan 9, 2025
Upgrades: Neutral
Price Target: $80 → $97
Current: $62.79
Upside: +54.48%
Integra LifeSciences Holdings
Oct 7, 2024
Maintains: Underperform
Price Target: $26 → $18
Current: $14.12
Upside: +27.48%
Integer Holdings
Oct 1, 2024
Maintains: Buy
Price Target: $135 → $145
Current: $109.58
Upside: +32.32%
Merit Medical Systems
Sep 16, 2024
Maintains: Neutral
Price Target: $92 → $103
Current: $86.10
Upside: +19.63%
Haemonetics
Sep 11, 2024
Initiates: Neutral
Price Target: $85
Current: $53.88
Upside: +57.76%
GE HealthCare Technologies
May 1, 2024
Maintains: Neutral
Price Target: $94 → $86
Current: $75.33
Upside: +14.16%
Oct 30, 2023
Initiates: Buy
Price Target: $95
Current: $74.24
Upside: +27.96%
Jan 18, 2022
Maintains: Buy
Price Target: $43 → $36
Current: $15.71
Upside: +129.15%
May 13, 2020
Reiterates: Overweight
Price Target: $23 → $45
Current: $8.85
Upside: +408.47%
Mar 25, 2020
Maintains: Overweight
Price Target: $15 → $120
Current: $3.19
Upside: +3,661.76%
Mar 24, 2020
Maintains: Neutral
Price Target: $60 → $30
Current: $5.18
Upside: +479.15%
Mar 24, 2020
Reiterates: Overweight
Price Target: $17 → $13
Current: $12.73
Upside: +2.12%
Feb 25, 2020
Maintains: Neutral
Price Target: $48 → $42
Current: $14.11
Upside: +197.66%
Jan 10, 2020
Reiterates: Overweight
Price Target: $207 → $230
Current: $482.35
Upside: -52.32%
Jul 26, 2019
Maintains: Neutral
Price Target: $190 → $230
Current: $378.95
Upside: -39.31%